Engflag

Novil

Quick links to important sections

Novil

Novil_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novil

Property Description
Active Ingredients Chlorzoxazone, Diclofenac Potassium, Paracetamol (Acetaminophen)
Form Oral Tablet
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID) and Centrally Acting Skeletal Muscle Relaxant combination
Common Purpose Integrated relief of pain, inflammation, and muscle spasm
Origin Synthetic

Novil: Classification and Core Identity

Novil is a Fixed-Dose Combination (FDC) medicinal product classified as a compound analgesic and a skeletal muscle relaxant, designed for oral systemic administration. This synthetic preparation is defined by the concurrent inclusion of three active ingredients that collectively address pain, inflammation, and muscle stiffness. The product’s classification identifies it as a multimodal approach, aiming to address the complex symptomatology often present in acute painful musculoskeletal conditions, a strategy widely recognized in clinical practice.

Composition and Triple-Action Profile

The drug’s triple-action efficacy is derived from its three synthetic active ingredients: Diclofenac Potassium, Paracetamol (Acetaminophen), and Chlorzoxazone. Diclofenac Potassium provides anti-inflammatory action, a mechanism clinically recognized for reducing tissue swelling and pain by inhibiting prostaglandin synthesis. Paracetamol contributes a central analgesic action and antipyretic action, complementing the peripheral effect. Uniquely, Chlorzoxazone functions as a Centrally Acting Skeletal Muscle Relaxant to relieve the involuntary muscle spasm that frequently accompanies soft tissue injury.

General Therapeutic Purpose

By delivering these three agents via a single oral dosage form, the overall purpose of Novil is to provide integrated management for the combined symptoms of pain, inflammation, and restrictive muscle spasm. The FDC offers a unified therapeutic strategy, intended to provide comprehensive relief from the discomfort and rigidity associated with painful muscle states, which is often utilized when both pain control and relief from muscle tightness are clinically necessary.

What side effects are possible with Novil?

Possible Side Effects and Safety Information: Novil

Documented Adverse Reactions

The full safety profile of Novil is derived from clinical trials and post-marketing surveillance data, which are formally compiled in regulatory documents (e.g., FDA-approved labeling, EMA Summary of Product Characteristics). The adverse reactions are generally categorized by the organ system they affect and their frequency.

Commonly Reported Adverse Reactions:

The most frequently reported side effects (occurring in approximately 1% to 10% of patients) often involve the gastrointestinal system and general constitutional symptoms. These may include nausea, diarrhea, vomiting, and headache. Injection-site reactions and inflammation are also common, particularly when the drug is administered intravenously.

Less Common and Serious Adverse Reactions:

Less frequently reported adverse events (occurring in less than 1% of patients) may involve more severe systemic effects. Serious and clinically significant reactions documented in regulatory sources typically include hypersensitivity reactions, such as severe allergic responses or anaphylaxis, which require immediate medical attention. Central nervous system effects, including seizures, have also been reported, particularly in individuals with pre-existing neurological conditions or compromised kidney function. Other serious but rare reactions involve severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, and hematological abnormalities like agranulocytosis or neutropenia.

Safety Considerations and Restrictions

  • Hypersensitivity: Novil is contraindicated in patients with a known severe hypersensitivity to the drug's components or to other agents in the same class. Severe allergic reactions have been documented.
  • Population Specific: Caution is advised in patients with impaired renal function, as this may increase the risk of adverse effects, including seizures. Dosage adjustments are often necessary for this population to mitigate risk.
  • Risk Mitigation: Regulatory labeling emphasizes that the drug should be used only for proven or strongly suspected bacterial infections to minimize the development of drug-resistant bacteria. Additionally, coadministration with certain other medications may be restricted due to potential for harmful drug-drug interactions, such as those that can lower the serum concentration of coadministered anticonvulsants, increasing the risk of breakthrough seizures.

Patients are advised to maintain open communication with their healthcare providers regarding any new or worsening symptoms.

Overdose and Emergency Response

The official regulatory profile for Novil overdose is defined by the combined severe toxicities documented for its three active components. Initial manifestations listed in prescribing information may include drowsiness, sluggishness, dizziness, nausea, vomiting, abdominal pain, and diarrhea. However, the most severe outcomes involve delayed, life-threatening organ damage that necessitates urgent action.

Regulatory documents confirm the risk of severe hepatotoxicity, liver failure, and death, primarily linked to the Paracetamol component. This damage can progress even if initial symptoms are mild. The Diclofenac component increases the potential for acute gastrointestinal bleeding, ulceration, and renal failure. Central Nervous System effects, including seizures, coma, and respiratory depression, are also documented risks.

Regulatory authorities mandate that immediate medical attention or advice must be sought for any known or suspected overdose, regardless of initial well-being, due to the critical risk of delayed organ damage. N-acetylcysteine (NAC) is designated as the specific antidote for Paracetamol toxicity, while no specific antidote is known for the other components. Treatment requires symptomatic and supportive measures, along with hospital monitoring of vital signs and laboratory results. The documentation also notes that hazards are greater in the elderly and those with non-cirrhotic alcoholic liver disease.

Therapeutic Uses of Novil

What Novil Treats: Main Uses and Benefits

Novil is a medicine commonly used across conditions presenting with acute episodes. It is applied across therapeutic domains where additional symptomatic support is needed. Novil may assist with supportive relief in situations involving certain distressing symptoms, such as those linked to inflammatory or musculoskeletal conditions.

The therapeutic benefits of this category of medication are considered relevant for managing symptoms related to physical discomfort. This includes: examples of symptoms related to physical discomfort that it is applied in addressing, such as pain, headache, and body aches. This category of medication is commonly used to help with symptoms related to inflammatory or irritative states. This class of medication supports patients during episodes of heightened discomfort by easing the overall symptom burden.

“It supports the patient during difficult episodes by easing distress and maintaining functional stability.”

Novil may assist with easing the overall symptom burden, which may include helping to address symptoms that become more disruptive during flare-ups and contribute to improved comfort during symptomatic periods. This provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Supports patients with symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus overview of Pain Relievers

Eligibility and Restrictions for Use

Novil is officially established for use in adults who do not present with specific regulatory exclusions. Its eligibility profile is strictly defined by the contraindications associated with its Diclofenac (NSAID) and Paracetamol components.

Eligibility Scope

Classification Population or Condition
Contraindicated Known hypersensitivity to any component (Diclofenac, Paracetamol, Chlorzoxazone) or other NSAIDs/aspirin.
Active or recurrent peptic ulceration or GI bleeding/perforation.
Severe hepatic or severe renal failure.
Severe uncontrolled heart failure (NYHA Class III-IV).
Third trimester of pregnancy.
Not Recommended Children and adolescents (under 18 years); use is not established.
Breastfeeding/Lactating women; use is not established.
First and second trimesters of pregnancy.

Eligibility-Related Restrictions

Use with Caution is required for older adults (geriatric population), patients with mild-to-moderate hepatic or renal impairment, and those with a history of hypertension or established cardiovascular risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Novil is a fixed-dose combination containing Diclofenac Potassium, Paracetamol, and Chlorzoxazone, and its official interaction profile inherits the risks of all three components, requiring mandatory restrictions and precautions as detailed in regulatory documents.

Contraindicated and Restricted Combinations

Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is generally restricted due to the increased cumulative risk of serious gastrointestinal and renal adverse events. Use with any other Paracetamol-containing product is strictly restricted to prevent exceeding the maximum daily dose and mitigating the risk of hepatotoxicity.

Pharmacodynamic and Pharmacokinetic Interactions

Interaction classifications include those that result in additive physiological effects and those that cause formal exposure alteration:

  • Central Nervous System (CNS) Depressants and Alcohol: Concomitant use may result in official additive CNS depression due to Chlorzoxazone. Alcohol also enhances the risk of hepatotoxicity from Paracetamol.
  • Anticoagulants (e.g., Warfarin): Co-administration increases the documented risk of bleeding.
  • Diclofenac-related exposure alteration: Diclofenac may increase the plasma concentrations of co-administered agents like Lithium, Digoxin, and Methotrexate due to reduced clearance, and may also reduce the activity of Diuretics.
  • Metabolic Risks: The risk of Paracetamol toxicity is increased by co-administration with drugs that act as hepatic microsomal enzyme inducers.

Specific caution is advised for elderly patients and those with existing hepatic or renal impairment, as these populations are at a heightened risk for severe interaction outcomes.

Mechanism of Action

Novil is a fixed-dose combination product containing three active pharmacological agents: Diclofenac, Paracetamol (Acetaminophen), and Chlorzoxazone.

The pharmacodynamic action of Diclofenac is mediated through non-selective inhibition of cyclooxygenase (COX-1 and COX-2) enzymes. This enzyme inhibition decreases the cellular biosynthesis of prostaglandins, lipid mediators involved in localized inflammation and nociceptive signaling. Downstream, this modulates peripheral and central components of pain pathways. Diclofenac also inhibits neutrophil aggregation, chemotaxis, and alters lymphocyte activity.

Paracetamol exerts its effects predominantly within the central nervous system. It acts centrally to inhibit prostaglandin synthesis, a mechanism distinct from peripheral COX inhibition. Furthermore, it modulates thermosensitive neurons within the hypothalamus to effect systemic heat dissipation.

Chlorzoxazone functions as a centrally acting muscle relaxant. Its mechanism involves general depression of the nervous system, specifically modulating polysynaptic reflex arcs located in the brain and spinal cord. This central modulation reduces the efferent signaling that governs skeletal muscle tone, leading to decreased muscle hypertonia.

Dosage and Administration Information

How to Use Novil

Novil is a medicine intended for oral systemic administration, delivered as a fixed-dose combination tablet. Official usage instructions define a precise protocol for dosing, frequency, and duration, based on the standard prescribing information for its components, Diclofenac, Paracetamol, and Chlorzoxazone.

Administration and Timing

Administration of the tablet is typically mandated with or immediately after food to help mitigate the potential for gastrointestinal discomfort associated with the Diclofenac component. The tablet must be swallowed whole with sufficient liquid.

Standard Dosage and Frequency

The standard regimen involves taking one tablet per dose, administered up to two or three times per day. A minimum interval, generally 6 hours, must be maintained between subsequent doses to ensure component levels remain within safe limits. Patients must strictly adhere to the established maximum daily dose for each active substance. This is particularly crucial for the Paracetamol component, where the total daily intake must not exceed 3000 mg to 4000 mg from all sources.

Course Duration and Adjustments

Novil is designated for short-term use only, typically limited to a course duration of 7 to 14 days to address acute episodes, as directed by official labeling. Use beyond this short course is not defined by standard acute-use protocols. For older adults and patients with known renal or hepatic impairment, standard clinical guidelines require that the lowest effective dose be used, with dose adjustment or exclusion necessary depending on the degree of impairment. If a dose is missed, it should be omitted, and the schedule should resume at the next designated time, without attempting to double the subsequent dose.

Recent Clinical Evidence

Evidence for Use in Acute Painful Musculoskeletal Conditions

Novil was studied for use in acute painful musculoskeletal conditions, such as acute lower back pain, that are accompanied by muscle spasm. The research primarily consists of short-term Randomized Controlled Trials (RCTs). These studies were evaluated in adult populations presenting with conditions characterized by acute or disruptive episodes where both pain and muscle stiffness are present.

Researchers examined a variety of outcomes related to physical discomfort, including using standardized tools to measure pain intensity, physical measurements of muscle spasm, and outcomes reflecting daily functioning. The trials reported measurements of symptom intensity and functional outcomes in the observed populations over defined, short time intervals, often a week or less.

The evidence base for this type of three-drug combination is categorized as moderate. This grading reflects the existence of research but also acknowledges the documented limitations regarding direct comparisons with relevant two-drug combinations.

Review of Study Duration and Research Gaps

The typical follow-up durations for the key comparative studies were limited, generally focusing on short-term use lasting for seven days or less. Because the research primarily examined temporary physiological imbalance, long-term effects are not fully established. There is limited information for long-term outcomes or data describing symptom patterns over periods longer than a few weeks.

Data for certain patient groups, such as older adults who may present with concurrent health conditions (comorbidities), remain insufficient. The results apply primarily to the adult populations studied, and subgroup findings are uncertain for specialized patient types.

Scientific reviews consistently highlight several areas where evidence is limited. A key limitation is the comparative evidence that is lacking for this specific triple combination. Overall, while studies help show what has been observed so far, findings describe group patterns, not personal outcomes, and the research provides context but does not determine whether an individual will respond similarly.

Key Studies & References F. No. 04-146/2007-DC - Recommendation of Experts Committee on Fixed Dose Combination of Diclofenac/Paracetamol/Chlorzoxazone

Frequently Asked Questions (FAQ)

Common questions about Novil (FAQ)

Q: Can I take Novil if I am pregnant or breastfeeding?

Official product information advises against the use of Novil during pregnancy, and it is contraindicated during the third trimester. This is due to known risks associated with the Diclofenac component.

Regarding use while breastfeeding, the safety is generally not established, and official guidance suggests caution.

Q: What is the highest dose I can take in one day?

Regulatory documents define a maximum daily dose for Novil that must not be exceeded. The regulatory limit for tablets per day is generally two or three, but this must be confirmed by a healthcare professional.

Regulatory documents emphasize that the total intake of the Paracetamol component from all sources (including Novil and other medicines) should not exceed 3000 mg to 4000 mg daily due to the potential risk of liver toxicity.

Q: What is the purpose of the three ingredients in Novil?

Novil is a combination medicine designed to address the complex symptoms often associated with painful musculoskeletal conditions. Its three active ingredients work together.

Official information states that Diclofenac provides anti-inflammatory action, Paracetamol contributes to pain relief, and Chlorzoxazone works as a centrally acting muscle relaxant to relieve muscle spasm.

Q: Can Novil be split or crushed to make it easier to swallow?

The official instructions for use state that the Novil tablet must be swallowed whole with sufficient liquid. The regulatory guidance requires that the tablet be swallowed whole and does not define a protocol for altering the tablet's form.

This instruction is intended to ensure the drug is administered as defined by the official prescribing information.

Q: Are there any foods or drinks I need to avoid while taking Novil?

Official warnings note a specific restriction regarding the consumption of alcohol.

Regulatory documents state that consumption of alcohol should be avoided while taking Novil, as this may increase the risk of liver damage from the Paracetamol component and enhance the sedating effect of Chlorzoxazone.

Q: How quickly does Novil start to work after taking a dose?

The speed at which any medicine begins to provide relief is related to how quickly the active substances are absorbed and reach their peak concentration in the bloodstream. This time is described in the Clinical Pharmacology section of the drug's regulatory label.

While individual response varies, the official label does provide technical details regarding the time it takes for the active substances to reach peak concentration in the blood (Tmax).

How should Novil be stored and disposed of?

How to Store and Dispose of Novil?

The official storage and disposal requirements for Novil (Chlorzoxazone, Diclofenac Potassium, Paracetamol Oral Tablet) are strictly defined by regulatory guidelines to ensure stability and public safety.

Official Storage Requirements

Condition Requirement
Temperature Store below 30 C (thirty degrees Celsius).
Protection Keep the product in a dry and cool place, protected from excessive heat, moisture, and sunlight.
Container Rule Keep the medication in the original container, and ensure the container is tightly closed.
Prohibition Do not freeze or refrigerate the tablets.
Safety Keep all medication out of the sight and reach of children and always secure safety caps.

Official Disposal Protocol

Unused or expired Novil should be disposed of using a local drug take-back program when available. The regulatory guidance for household disposal, if a take-back site is inaccessible, requires mixing the tablets with an unappealing substance (such as dirt or coffee grounds) in a sealed bag before placing it in the trash. Do not flush Novil down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Novil found in:

A-Z Index: